Adjuvant treatment of malignant melanoma;Die adjuvante Therapie des malignen Melanoms

Praxis

Volumn 90, Issue 8, 2001, Pages 301-306

  Franke, W ^a   Neumann, N J ^a   Ruzicka, T ^a   Schulte, K W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adjuvant therapy; Chemotherapy; Immunotherapy; Malignant melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA INTERFERON; DACARBAZINE; GANGLIOSIDE GM2; INTERFERON; INTERLEUKIN 2;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG COST; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUMOR VOLUME;

BCG VACCINE; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; INTERFERON ALFA-2B; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0035931953     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Balch C.M., Milton G.W., Shaw H.M., Soong S.-J.: Hautmelanome. Springer Berlin.
2. Balch C.M., Smalley R.V., Bartolucci A.A.: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma. Prognostic factors analysis and preliminary results of immunotherapy. Cancer 49, 1079-1084, 1982.
3. Beiteke U., Ruppert P., Garbe C.: Adjuvant Therapie des primären malignen Melanoms mit natürlichen humanen Interferon beta. Hautarzt 44, 365-371, 1993.
4. Bröcker E.-B., Suter L., Czarnetzki B.M., Macher E.: BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors? Cancer Immunol. Immunother. 23, 155-157, 1986.
5. Bröcker E.-B., Macher E., Sorg C.: Changes in the tumor-associated inflammatory infiltrates in the course of local and systemic progression of cutaneous melanoma. In: Ferrone S. (Hrsg.): Human melanoma. From basic research to clinical application. Springer Berlin, 278-293, 1990.
6. Bystryn J.C.: Vaccines for melanoma. Design strategies and clinical results. Dermatol. Clin. 16, 269-275, 1998.
7. Carrell S., Johnson J.P.: Immunologie recognition of malignant melanoma by autologous T lymphocytes. Curr. Opin. Oncol. 5, 383-389, 1993.
8. Cascinelli N., Bufalino R., Morabito A., MacKie R.: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343, 913-914, 1994.
9. Coit D.G.: Hyperthermic limb perfusion for malignant melanoma: a review. Cancer Invest. 10, 277-284, 1992.
10. Crowley N.J.: The case against elective lymphadenectomy. Surg. Oncol. Clin. North Am. 1, 223-243, 1992.
11. Czarnetzki B.M., Macher E., Sucui S.: Longterm adjuvant immunotherapy in stage-I high-risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomized multicentre study (EORTC-Protocol 18781). Eur. J. Cancer 29a, 1237-1242, 1993.
12. Ghussen F., Krüger I., Groth W., Stützer H.: Randomisierte Melanom-studie zur Extremitätenperfusion. Behandlungsergebnisse 2 1/2 Jahre nach vorzeitigem Abbruch. Chirurg 57, 619-623, 1986.
13. Grob J.J., Dreno B., Delaunay M.: Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (> 1,5mm). Proc ASCO 437, 1996.
14. Hill G.J., Moss S.E., Colomb F.M.: DTIC and combination therapy for melanoma: III: DTIC (NSC 45388) surgical adjuvant study COG protocol 7040. Cancer 47, 2556-2562, 1981.
15. Israel R.J.: Phase II and III clinical development of GM2-KLH/QS-21 vaccine for melanoma. Melanoma Res. 7, 52, 1997.
16. Kirkwood J.M., Strawderman M.H., Ernstoff M.S.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial 1684. J. Clin. Oncol. 14, 7-17, 1996.
17. Livingston P.O., Wong G.Y.C., Adluri S.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036-1039, 1994.
18. Lu C., Kerbel R.S.: Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr. Opin. Oncol. 6, 212-220, 1914.
19. Lynch S.A., Houghton A.N.: Cancer immunology. Curr. Opin. Oncol. 5, 145-150, 1994.
20. Meyskens F.L., Kopecky K., Samson M.: Recombinant human interferon gammA: Adverse effects in high-risk stage I and II cutaneous malignant melanoma. J. Natl. Cancer Inst. 82, 1071, 1990.
21. Orfanos C.E., Jung E.G., Rassner G.: Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Hautarzt 45, 285-291, 1994.
22. Quirt I.C., Shelley W.E., Pater J.L.: Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 9, 729-735, 1991.
23. Ross M.I.: Surgery and other local-regional modalities for all stages of melanoma. Curr. Opin. Oncol. 6, 197-203, 1994.
24. Thomas M.R., Robinson W.A., Glode L.M.: Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results. Am. J. Clin. Oncol. 5, 611, 1982.
25. Vrouenraets B.C., Kroon B.B.R., Klaase J.M.: Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities. J. Surg. Oncol. 52, 249-254, 1993.
26. Wallack M.K., Sivanandham M., Balch C.M.: A phase III randomized, double-blind, multiinstitutional trial of vaccina melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75, 34-42, 1995.
27. Wolchok J.D., Livingston P.O., Houghton A.N.: Vaccines and other adjuvant therapies for melanoma. Hematol/Oncol. Clin. North Am. 12, 835-845, 1998.